IMVT Immunovant

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12th-14th, 2022.

H.C. Wainwright Global Investment Conference fireside chat details:

Date:Thursday, September 14th, 2022
  
Time:4:00 pm Eastern Time
  
Webcast:The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at .

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As a leader in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs. The Company’s investigational compound, batoclimab, is a novel, fully human, monoclonal antibody targeting the neonatal Fc receptor (FcRn). For additional information on the Company, please visit . 

Contact:

Tom Dorney, MS, MBA

Director, Investor Relations & Strategy

Immunovant, Inc.



EN
09/09/2022

Underlying

IMVTImmunovant

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunovant

 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Corporate Updates and Reports Financial Results fo...

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 Initiated a second potentially registrational study of IMVT-1402 in Graves’ disease (GD) and a potentially registrational study of IMVT-1402 in Sjögren’s disease (SjD), both in June 2025All other clinical trials in previously announced six-indications remain on track with increased focus on clinical executionRemission data from the batoclimab proof-of-concept study in GD to be reported at the American Thyroid Association (ATA) Annual Meeting in September 2025Current cash balance provides ...

August 11, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Provides Corporate Updates and Reports Financial Results fo...

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 Immunovant’s new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves’ disease (GD) and a potentially registrational study in Sjögren’s disease (SjD), both expected to start in summer 2025Positive data from first-generation batoclimab trials in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) demonstrated that deeper Ig...

May 29, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Announces Next Phase of Growth with Roivant Including Chang...

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 Eric Venker, M.D. (currently President and COO of Roivant) appointed as CEO of Immunovant and Tiago Girao appointed as CFO of ImmunovantPete Salzmann, M.D. retired from his role as Immunovant CEO and DirectorLeadership change is part of a broader strategic transition with Roivant increasing operational involvement and strategic oversight of Immunovant  IND cleared for a potentially registratio...

April 21, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis...

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% ...

March 19, 2025 1 EN
 PRESS RELEASE
Free
IMVT IMMUNOVANT

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March ...

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. ...

March 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch